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Acute respiratory distress syndrome (ARDS) is common in critically ill patients admitted to intensive care units (ICU).
ARDS results in increased use of critical care resources and healthcare costs, yet the overall mortality associated
with these conditions remains high. Research focusing on preventing ARDS and identifying patients at risk of
developing ARDS is necessary to develop strategies to alter the clinical course and progression of the disease. To
date, few strategies have shown clear benefits. One of the most important obstacles to preventive interventions is
the difficulty of identifying patients likely to develop ARDS. Identifying patients at risk and implementing prevention
strategies in this group are key factors in preventing ARDS. This review will discuss early identification of at-risk
patients and the current prevention strategies.Review
Introduction
Acute respiratory distress syndrome (ARDS) is common in
critically ill patients admitted to intensive care units (ICU).Multiple hit model for ALI/ARDS development
Previous studies support a two-hit model of ARDS develop-
ment in which exposure to pertinent risk factors modifies
the development and expression of ARDS in a host with
predisposing conditions [1-3]. However, beyond the devel-
opment of ARDS in a susceptible host, theories of the
pathogenesis of this condition should explain progression
from an initial lung injury to mild ARDS or from mild or
moderate to severe ARDS. To this end, a chain reaction
based on multiple hits can be involved in the pathogenesis
of ARDS development and/or the progression of severity
[4]. Host predisposing conditions act as a first hit in healthy
lungs, where multiple hit can induce ARDS. In the absence
of these predisposing conditions, the probability that the
other hits would result in ARDS is lower. Whether the dis-
ease progresses from an initial injury to ARDS or continues
to progress from mild-moderate ARDS to severe ARDS
probably depends on a chain reaction based on these mul-
tiple hits (Figure 1).* Correspondence: cdeharo@tauli.cat
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in any medium, provided the original work is pHudson et al. [5] found the presence of one or more
of eight clinical conditions (sepsis, aspiration, drug over-
dose, near-drowning, pulmonary contusion, multiple
transfusions, multiple fractures, head trauma) predicted
whether ARDS develops with 79% sensitivity but only
26% specificity. Fowler et al. [6] found pneumonia, aspir-
ation, and disseminated intravascular coagulation were
the strongest predictors but only 7% of the patients with
one or more predisposing factors developed ALI. Gong
et al. [7] showed the risk of ARDS increased with a
pulmonary etiology of injury, hematologic failure, trans-
fusion of eight or more units of packed red blood cells,
respiratory rate > 33 breaths/min, hematocrit > 37.5%,
arterial pH < 7.33, albumin ≤ 2.3 g/dL, and transfer from
another hospital. In another study in non-ICU hospital-
ized patients, Ferguson et al. [8] found that pulmonary
risk conditions had a higher rate of progression to
ARDS than nonpulmonary conditions, but shock was
the strongest predictor. Therefore, by halting this
unvirtous circle might help to stop the progression to
ARDS.
Towards prevention. Early recognition
Identification of patients at risk
The first obstacle to preventing ARDS is identifying
patients at risk of developing ARDS [9]. Many authors
have proposed clinically detectable predisposing factors
and even scores to identify patients at risk early in the
course of the disease. Implementing preventive measuresan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 Multiple-hit model. A chain reaction of predisposing conditions and multiple hits (modifiers factors and treatments) in healthy lungs
can develop mild, moderate or severe ARDS.
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rithms have been proposed. Trillo-Alvarez et al. [10]
developed an ALI prediction score, the lung injury pre-
diction score (LIPS), that identifies patients at high risk
for ALI before ICU admission. Risk factors are divided
into predisposing conditions (sepsis, shock, pneumonia,
aspiration, trauma, and high risk-surgery) and risk modi-
fiers (obesity, alcohol abuse, diabetes, hypoalbuminemia,
acidosis, tachypnea, and oxygen supplementation). Gajic
et al. [11] validated this score in a prospective, multi-
center, observational study, demonstrating that the
LIPS model discriminates efficiently between patients
who have a low risk of developing ARDS and those
with high risk (AUC = 0.8), while maintaining an ap-
propriate sensitivity for screening (negative predictive
value (NPV) = 0.97).
In 2010, Thakur et al. [12] reported a cohort study
designed to identify patients at risk early before ARDS
develops, using an electronic medical record that facil-
itates early recognition of specific criteria, based on a
previously validated ARDS sniffer (NPV = 0.99, 95%
confidence interval (CI) 0.98-1.00) [13]. They identi-
fied patients at risk by the LIPS score and recorded
hospital-acquired exposures that may modify the risk
of ARDS and its impact on subgroups of high-risk pa-
tients. Levitt et al. [14] proposed the term “early ALI”
(EALI). EALI identified patients progressing to ARDS
with a sensitivity of 73% and a specificity of 79%. The
combination of early clinical recognition and predictive
scores could help in the detection of patients at-risk and
in the early treatment or implementation of preventive
strategies.Biomarkers
Identifying a biomarker that predicts the development
of ARDS or progression of severity could be helpful.
The ideal biomarker would be easy and safe to collect,
easily measured and reproducible, highly sensitive and
specific in predicting clinical outcome, and have a de-
fined role in the pathogenesis of ARDS [15]. Unfortu-
nately, no single biomarker is currently specific or
sensitive enough to be incorporated into routine clinical
practice.
Volatile organic compounds in exhaled air may differ
between diseases. Bos et al. [16,17] conducted two studies
where they discriminated between mechanically ventilated
patients with and without ARDS on the basis of a
breathprint obtained by analyzing exhaled air through
eNose technology. This breathprint distinguished be-
tween patients with ARDS and those without as accur-
ately as PaO2/FiO2 assessment. Noninvasive analysis of
exhaled air may help to identify a biomarker to detect
ARDS in an early stage, before clinical signs; however,
further studies are needed before this approach can be
incorporated into routine clinical practice.
Other biomarkers in plasma or bronchoalveolar lav-
age fluid have been studied in patients with ARDS. A
recent trial in critically ill patients demonstrated that
higher levels in plasma of angiopoetin-2 were signifi-
cantly associated with increased development of ALI
(odds ratio (OR) 2.4; 95% CI 1.3-4.2) [18].
Furthermore, the association of angiopoetin-2 levels
and the LIPS improved the AUC to 0.84. Because there is
no ideal biomarker to help us in the early detection of
ARDS, the association between biomarkers and different
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could improve prediction scores [19,20].
Genetic predisposition
There is some evidence that genetic factors predispose to
the development of ARDS and poor prognosis. Copland
et al. [21] used an experimental model of acute ventilator-
induced lung injury (VILI) to determine which genes
changed their expression depending on inspiratory volumes,
and they identified various genes with overexpression. One
of the most important studies is from Grigoryev et al.
[22], who identified 85 genes important in the patho-
genesis and different biologic processes involved in
the development of ARDS.
Nevertheless, at present, we cannot identify a single gene
responsible for a high susceptibility to ARDS. Some studies
are currently trying to evaluate the role of single nucleotide
polymorphism (SNPs) and haplotypes in order to better de-
tect patients at ARDS risk. These studies could help to de-
fine new therapeutic targets, new approaches to treatment,
and individual indicators of predisposition to developing
the disease that might enable the development of effective
preventive strategies.
Pathogen virulence
Defining risk factors associated with the development of
ARDS in patients with an infectious disease is challenging
because virulence factors of different pathogens have been
implicated in causing lung damage. Bacterial products are
directly toxic to the lung epithelium, independent of host
inflammatory responses and other factors [23]. Kojicic et al.
[24] recently found that the risk of hospitalized patients
with infectious pneumonia developing ALI varied with the
pulmonary pathogens.
Preventive measures
Beyond the etiology, certain modifiable external factors
can accelerate the development of ARDS.
Mechanical ventilation
Lung protective ventilation Lung-protective mechanical
ventilation strategies are the only supportive therapy that
clearly improve survival in patients with ARDS. However,
mechanical ventilation can lead to lung injury by different
mechanisms, with subsequent diffuse alveolar damage, pul-
monary edema, and local production of inflammatory me-
diators. This circumstance is known as VILI.
Tremblay et al. [25] showed that mechanical ventilation
with high volumes and without positive end-expiratory
pressure (PEEP) could increase tumor necrosis factor
(TNF-alpha) and interleukin-6 (IL-6) concentrations in
bronchoalveolar lavage fluid, whereas cytokine levels are
lower if protective mechanical ventilation is used. Amato
et al. [26] demonstrated lower mortality in patients ventilatedwith a limited tidal volume to avoid overdistension. A pro-
spective, multicenter trial (ARDS Network) published in 2000
confirmed that mechanical ventilation with lower tidal
volume (6 mL/Kg predicted body weight (PBW))
resulted in an increase in the number of ventilator-
free days and a reduction of in-hospital mortality
[27].
Mechanical ventilation is an important factor in the treat-
ment of ARDS, but is it important in prevention? Does
mechanical ventilation work as a risk modifier in patients
at risk? Could we help to prevent the development of
ARDS by applying protective mechanical ventilation in
patients at risk?
In a recent study, our group found that septic patients
without ARDS ventilated with a protective strategy using a
plateau pressure < 30 cmH20 had better outcomes and a
lower incidence of ARDS than those ventilated without this
limit on plateau pressure [28]. Thus, it may be beneficial to
implement protective ventilation strategies from the start of
mechanical ventilation, not only when ARDS appears. It re-
mains to be determined whether only plateau pressure
should be targeted or whether tidal volume should be
targeted too. In our opinion, preventive strategies also
should include protective ventilation with low tidal volume
in patients at risk, and some studies support this approach.
In 2004, Gajic et al. [29] reported that in ventilated patients
without ARDS large tidal volumes (11.4 mL/kg PBW for
women and 10.4 mL/kg PBW for men) were independently
associated with the development of ARDS. In a prospective
trial, Determann et al. [30] randomized patients who re-
quired mechanical ventilation to receive low tidal volume
(6 mL/kg PBW) or conventional tidal volume (10 mL/kg
PBW); the trial was stopped prematurely because more pa-
tients in the conventional tidal-volume group developed
ARDS than in the lower tidal-volume group (13.5 vs. 2.6;
p = 0.01).
Interestingly, the use of protective ventilation in “healthy
lungs” seems to be a field for further research. A recently
published meta-analysis, including eight trials that evalu-
ated two types of mechanical ventilation in patients with
uninjured lungs in the operating room, demonstrated a
decrease in lung injury development, pulmonary infection,
and atelectasis using lower tidal volumes and high PEEP
[31]. These results support the previous meta-analysis that
demonstrated only an attenuation of the development of
lung injury, conducted with trials that included patients in
operating room and ICU [32].
No concrete ventilation strategies have been established
for patients without ARDS who require mechanical venti-
lation. We think that ventilation with low tidal volumes
and plateau pressure < 30 cmH2O is a reasonable preven-
tion strategy of ARDS. Side effects associated with low
tidal volumes seem to be minimal. However, based on a
review by Schultz et al. [33], most studies favoring low tidal
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flammatory mediators instead of clinical outcomes, so pro-
spective trials should be done to evaluate the clinical
impact of this ventilatory strategy.
PEEP strategies
The use of prophylactic PEEP in patients without ARDS is
controversial. Various authors have demonstrated that
prophylactic PEEP decreases the incidence of ARDS
and PEEP may protect the lung after different types
of insults. In the 1970s it was demonstrated that
intraoperative use of PEEP reduced ARDS development
[34] and the use of early prophylactic PEEP reduced the
incidence of ARDS [35]. Other studies demonstrated that
the use of certain amount of PEEP reduced the intensity of
lung injury from different aggressions, as Dreyfuss et al.
showed in 1988 with the reduction of edema and preserva-
tion of the normal structural aspect of alveolar epithelium
using high levels of PEEP [36,37]. However, other studies
have refuted this effect. Pepe et al. conducted a trial where
found that the early application of PEEP in high-risk pa-
tients had no effect on the incidence of ARDS [38].
Manzano et al. [39] conducted a randomized trial where
nonhypoxemic patients without lung injury received 5
cmH2O or 8 cmH2O PEEP versus no PEEP. They found no
differences between groups in the development of ARDS,
but the proportion of patients who developed hypoxemia
was significantly higher in the no-PEEP group and the
PEEP group developed less ventilator-associated pneumo-
nia (relative risk (RR) 0.37; 0.15-0.84).
The use of higher tidal volumes, based on older strat-
egies, arose from a need to prevent atelectasis. PEEP strat-
egies are now better understood and the risk of over
distension better appreciated. So, this need has lessened.
Supportive treatments
Fluid balance
Fluid balance is an important risk modifier in the
development of ARDS. Pulmonary edema is largely due to
increased capillary permeability but is exacerbated by in-
creased hydrostatic pressures and oncotic pressure falls
[40]. The first reports about fluid strategies date from
1987, when Simmons et al. [41] observed that outcomes
in ARDS patients were better if they lost body weight and
had a lower fluid balance. Sakr et al. [42] in a cohort ob-
servational study showed that a higher mean fluid balance
was independently associated with increased mortality in
patients with ARDS. In 2006, the ARDS Network pub-
lished the results of a prospective, randomized trial com-
paring conservative and liberal fluid strategies in patients
with ARDS. The authors included patients after 48 hours
of ICU admission and with systolic blood pressure > 60
mmHg. The primary outcome (60-day mortality) did not
differ between groups, but the conservative group hadbetter oxygenation index and lung injury scores, as well
as more ventilator-free days [43]. A limitation of this
study is the exclusion of hemodynamically unstable pa-
tients that difficult the generalization of the results to all
patients with ARDS. On the other hand, Murphy et al.
[44] showed in a retrospective analysis of patients with
septic shock and ARDS that an adequate initial fluid re-
suscitation during the first 2 consecutive days coupled with
conservative fluid management after that was associated
with the lowest mortality. Despite the above, no random-
ized trials have been done evaluating a two-phase fluid
management strategy that could confirm this strategy.
Thus, in patients with established ARDS, it seems that a
conservative fluid strategy should be used, but it is difficult
to know the role of fluid balance in the absence of ARDS.
Sepsis management
Sepsis precipitates ARDS in 25% to 40% of cases,
and the risk increases if a systemic inflammatory re-
sponse, shock, or organ dysfunction is present. The
most frequent etiology is pneumonia, followed by
nonpulmonary infections [45]. There is no specific pre-
ventive treatment against the development of ARDS in
patients with sepsis. Novel therapies are being studied,
but no promising results have been reported. It seems
that early detection of patients with sepsis who are at
risk of developing ARDS is one way to achieve better
results in the earliest phase. Indeed, one of the most
important preventive strategies is to ensure adequate
management of sepsis, including source control and
early appropriate antibiotic therapy [46,47].
Restrictive transfusion
Several studies have demonstrated an association be-
tween the transfusion of blood products and ARDS.
Zilberberg et al. [48] showed that more patients who
developed ARDS had received red cell transfusions
than those who did not develop ARDS; moreover, they
found that transfusion of greater amounts increased
the risk of developing ARDS. Many authors have since
confirmed this association [7,45,49,50].
Transfusion-related acute lung injury (TRALI) is defined
as new ARDS during or within 6 hours after an infusion of
one or more plasma-containing or plasma-derived blood
products [51].
The neutrophil has been postulated that is the respon-
sible cell in the pathogenesis of TRALI. In 1985 Popovsky
et al. published a sequence of patients who developed
TRALI after blood transfusion and demonstrated the pres-
ence of leukocyte antibodies and antibodies anti-HLA in a
high percentage of blood donators. It was thought that do-
nors’ antibodies were responsible of TRALI, but some
transfused patients did not develop TRALI despite the
presence of leukocyte antibodies [52].
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two hits: first, a lung injury in the lung epithelium causes
sequestration of neutrophils in the lungs, and second, the
transfusion of blood storage causes liberation of cytotoxic
factors and capillary damage. This concept is because blood
storage products are correlated with a high development of
transfusion reactions, and factors responsible of these reac-
tions increase with time of storage [53].
The activated neutrophils release oxygen radicals and
other elements that damage the lung endothelium. Despite
this, there are clinical and experimental evidence of TRALI
without neutrophil primo activation, but it is the underlying
disease that activates the endothelium and after that neu-
trophils are recruited in lung capillaries.
These theories of pathogenesis suggest different
preventive strategies. Several studies have demon-
strated worse outcomes after donation from multipar-
ous women, because the likelihood of HLA and HNA
immunization increases with the number of pregnan-
cies [54-56]. Because of this, many authors suggest the
restriction of women donors [57-59]. Although it could
seem disproportioned, the option of the screening of
donors is expensive and not available in all sites.
The strategy of reduction the time of blood storage
seems reasonable to prevent nonimmune TRALI. Another
option is the leukoreduction, reducing the activity of
preactivated neutrophils. It has been introduced in many
countries [60]. An adequate policy of transfusion focused
on less transfusion is perhaps the most important preven-
tive strategy [61].
Specific strategies
Many trials are underway to test whether different
pharmacologic treatments have beneficial effects, but
many pharmacologic therapies that prove effective in
animal models fail in human studies. To date, there is
no specific pharmacologic treatment for the prevention
of ALI/ARDS.Figure 2 Preventive approaches to ARDS.Activated protein C
Activated protein C (APC) has several anti-inflammatory
effects that may reduce the likelihood and severity of
lung injury. In ARDS, acute inflammation in pulmonary
compartments is characterized by fibrin formation, cyto-
kine production, and protein leakage into the alveolar
space due to increased capillary barrier permeability and
neutrophil migration. All of these are potential targets of
recombinant human APC. Local administration of APC
would be a good treatment strategy in ARDS, avoiding
the bleeding complications associated with systemic
administration.
It might be feasible to administer APC to ARDS pa-
tients by inhalation. Administering inhaled APC to
mice significantly reduced lipopolysaccharide-induced
pulmonary inflammation [62]. Another experimental
study tested the preventive effect of inhaled APC
against lung injury in mice and found a reduction in
lung injury induced by mechanical ventilation in the
group that received inhaled APC [63].
Nevertheless, the evidence supporting the use of APC is
not strong enough to recommend it for the prevention of
ARDS. We need more studies.Mesenchymal stem cells
Recent studies using experimental models of ALI have
demonstrated that the transplantation of mesenchymal
stem cells (MSCs) improves the regeneration of lung
tissue [64]. The benefits MSCs are derived not only
from the incorporation of these cells in the damaged
lung, but also from their interaction with damaged
lung cells and immunologic modulation. Most of these
studies administered MSCs as a pretreatment; one
study in rats showed pretreatment with MSCs reduced
VILI [65]. However, the use of MSCs is still highly ex-
perimental and more studies are necessary before they
can be applied as a treatment or prevention strategy.
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Aspirin, statins, inhaled corticosteroids, and beta-2 adrener-
gic agonists have been tested in experimental studies but
have yet to show promising results in human patients.
More studies are necessary before these drugs can be incor-
porated into preventive strategies [66]. Although there is
still a long way to go in the ARDS prevention field, some
new strategies and preliminary studies promise to improve
the early identification and early intervention to prevent the
progression of the disease (Figure 2).
Conclusions
ARDS is a common and devastating complication after
acute illness or injury, and it results in high morbidity,
mortality, and healthcare costs. Lung-protective ventila-
tion and appropriate sepsis management seems to be the
only strategies proven to improve outcomes in ARDS
patients; preventive strategies are a new field of research
aiming to avoid the progression of the disease. To date,
few preventive strategies have shown clear benefits. The
combination of early clinical recognition and predictive
scores could help to identify patients at risk and those
who might progress to mild, moderate, or severe ARDS.
The titration of tidal volume and the duration of mech-
anical ventilation in patients without ARDS seem to be
the best strategy for prevention.
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